Among rheumatoid arthritis (RA) patients treated with biologic drugs known as TNF inhibitors, the Vectra DA test provides information about RA disease activity and response to treatment. These results were presented at the 2012 annual meeting of the American College of Rheumatology.
Regular and systematic assessment of RA disease activity plays a key role in the management of this condition. Disease activity refers to ongoing inflammation, symptoms, and/or joint damage. Information about the level of disease activity allows doctors to monitor response to treatment and to adjust treatment as needed. Commonly used measures of disease activity consider factors such as counts of tender and swollen joints, patient self-assessment of health, and lab tests to identify inflammation.
A newer way to measure disease activity is the Vectra DA test, which is a blood test that allows doctors to test for several biological markers (or biomarkers) of RA simultaneously. Vectra DA measures the levels of 12 proteins in the blood—biomarkers that have been linked to RA disease activity—and then combines them into a single score (between 1 and 100) that classifies the current level of RA disease activity as “low”, “moderate”, or “high”.
To evaluate the performance of Vectra DA among patients treated with a TNF inhibitor, researchers conducted a study among 147 patients. The TNF inhibitors that were used by the study participants were Humira® (adalimumab), Enbrel® (etanercept), and Remicade® (infliximab).
- The Vectra DA result corresponded with clinical measures of disease activity: the Vectra DA score decreased when there was a response to treatment.
- The ability of the Vectra DA test to measure disease activity was similar regardless of the type of TNF inhibitor that the patient was taking.
These results indicate that Vectra DA can be used to track and manage treatment response among RA patients being treated with a TNF inhibitor.
Reference: Hirata S. A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab. Presented at the 2012 Annual Meeting of the American College of Rheumatology. Washington, DC. November 10-14, 2012. Abstract 2664.